Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.

Abrilumab effective for ulcerative colitis

23 Mar 2019

The monoclonal antibody abrilumab is effective for treating moderate-to-severe ulcerative colitis, promoting remission, clinical response and mucosal healing, a recent study has found.

Researchers randomly assigned 354 ulcerative colitis patients with inadequate responses to conventional therapies to receive abrilumab 7 mg every 4 weeks (n=21), 21 mg every 4 weeks (n=40), 70 mg every 4 weeks (n=98) or 210 mg at day 1 (n=79); or placebo (n=116). Study endpoints included remission, response and mucosal healing.

The unadjusted remission rates at 8 weeks were 4.3 percent, 0.0 percent, 2.5 percent, 13.3 percent and 12.7 percent for the placebo, 7-mg, 21-mg, 70-mg and 210-mg groups, respectively. Patients who received the two highest abrilumab doses were significantly likely to achieve remission than those who were given placebo (70 mg: odds ratio [OR], 3.35; 95 percent CI, 1.41–7.95; p=0.021; 210 mg: OR, 3.33; 1.34–8.26; p=0.030).

Unadjusted response rates at 8 weeks for the placebo, 7-mg, 21-mg, 70-mg and 210-mg groups were 25.9 percent, 14.3 percent, 50.0 percent, 49.0 percent and 46.8 percent, respectively.

Similarly, those given the highest two abrilumab doses were significantly more likely to achieve response at 8 weeks (70 mg: OR, 2.78; 1.71–4.52; p<0.001; 210 mg: OR, 2.57; 1.53–4.51; p=0.003).

The same was true for mucosal healing (70 mg: OR, 2.34; 1.35–4.07; p=0.011; 210 mg: OR, 2.10; 1.15–3.82; p=0.041). The corresponding unadjusted mucosal healing rates at 8 weeks were 21.6 percent, 14.3 percent, 15.0 percent, 32.7 percent and 29.1 percent for the placebo, 7-mg, 21-mg, 70-mg and 210-mg groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.